UroGen settles patent litigation with Teva over Jelmyto; generic entry Sept 15, 2030

UroGen Pharma Ltd.

Settlement resolves patent litigation regarding Teva's generic version of Jelmyto (mitomycin) for pyelocalyceal solution.
Teva granted non-exclusive license to sell generic Jelmyto starting September 15, 2030, if FDA approved.
All ongoing patent litigation between the parties in U.S. District Court for Delaware will be terminated.
Agreement is subject to review by U.S. Federal Trade Commission and U.S. Department of Justice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.